Greg A. Lazar

4.8k total citations · 3 hit papers
44 papers, 3.5k citations indexed

About

Greg A. Lazar is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Immunology. According to data from OpenAlex, Greg A. Lazar has authored 44 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Radiology, Nuclear Medicine and Imaging, 27 papers in Molecular Biology and 13 papers in Immunology. Recurrent topics in Greg A. Lazar's work include Monoclonal and Polyclonal Antibodies Research (34 papers), Glycosylation and Glycoproteins Research (10 papers) and Protein purification and stability (10 papers). Greg A. Lazar is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (34 papers), Glycosylation and Glycoproteins Research (10 papers) and Protein purification and stability (10 papers). Greg A. Lazar collaborates with scholars based in United States, Netherlands and United Kingdom. Greg A. Lazar's co-authors include John R. Desjarlais, Paul J. Carter, Sher Karki, Hsing Chen, Tracy M. Handel, Wei Dang, Gregory L. Moore, Irene Leung, Holly M. Horton and Jonathan Zalevsky and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Greg A. Lazar

44 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Engineered antibody Fc variants with enhanced effector function

2006 590 citations Greg A. Lazar, Wei Dang et al. Proceedings of the National Academy of Sciences profile →
Next generation antibody drugs: pursuit of the 'high-hanging fruit'

2017 564 citations Paul J. Carter, Greg A. Lazar Nature Reviews Drug Discovery profile →
Avidity in antibody effector functions and biotherapeutic drug design

2022 141 citations Greg A. Lazar et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Greg A. Lazar United States	24	2.2k	2.1k	1.2k	755	239	44	3.5k
William F. Dall’Acqua United States	36	2.4k 1.1×	2.6k 1.2×	1.1k 0.9×	646 0.9×	228 1.0×	79	4.1k
Paul J. Carter United States	22	2.8k 1.3×	2.9k 1.4×	1.2k 1.0×	1.3k 1.8×	175 0.7×	42	4.8k
John R. Desjarlais United States	37	1.7k 0.8×	2.8k 1.3×	1.1k 1.0×	813 1.1×	675 2.8×	88	4.3k
Thomas Garrett Australia	29	1.8k 0.8×	2.7k 1.3×	1.5k 1.3×	1.8k 2.4×	182 0.8×	49	5.4k
Guy Georges Germany	27	2.0k 0.9×	2.0k 0.9×	852 0.7×	553 0.7×	82 0.3×	66	3.1k
Patrick Chames France	34	2.0k 0.9×	2.5k 1.2×	1.3k 1.2×	1.2k 1.6×	232 1.0×	91	4.3k
Jefferson Foote United States	21	2.1k 0.9×	2.1k 1.0×	875 0.8×	439 0.6×	199 0.8×	30	3.3k
Nathalie Corvaı̈a France	31	2.4k 1.1×	2.6k 1.3×	1.0k 0.9×	1.6k 2.1×	69 0.3×	72	5.0k
Daniel Christ Australia	31	1.3k 0.6×	2.0k 1.0×	1.3k 1.1×	434 0.6×	82 0.3×	78	3.7k
Arvind Rajpal United States	28	1.4k 0.6×	1.5k 0.7×	874 0.8×	590 0.8×	71 0.3×	55	2.7k

Countries citing papers authored by Greg A. Lazar

Since Specialization

Citations

This map shows the geographic impact of Greg A. Lazar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Greg A. Lazar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Greg A. Lazar more than expected).

Fields of papers citing papers by Greg A. Lazar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Greg A. Lazar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Greg A. Lazar. The network helps show where Greg A. Lazar may publish in the future.

Co-authorship network of co-authors of Greg A. Lazar

This figure shows the co-authorship network connecting the top 25 collaborators of Greg A. Lazar. A scholar is included among the top collaborators of Greg A. Lazar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Greg A. Lazar. Greg A. Lazar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lafrance‐Vanasse, Julien, Shraddha Sadekar, Yanli Yang, et al.. (2025). Leveraging neonatal Fc receptor (FcRn) to enhance antibody transport across the blood brain barrier. Nature Communications. 16(1). 4143–4143. 4 indexed citations

Romei, Matthew G., Brandon Leonard, Zachary Katz, et al.. (2024). i-shaped antibody engineering enables conformational tuning of biotherapeutic receptor agonists. Nature Communications. 15(1). 642–642. 11 indexed citations

Besla, Rickvinder, Elicia Penuel, Ely Cosino, et al.. (2023). T cell–Dependent Bispecific Therapy Enhances Innate Immune Activation and Antibody-Mediated Killing. Cancer Immunology Research. 12(1). 60–71. 6 indexed citations

Romei, Matthew G., Kannan Sankar, Lipika R. Pal, et al.. (2022). Antibody interfaces revealed through structural mining. Computational and Structural Biotechnology Journal. 20. 4952–4968. 4 indexed citations

Carter, Paul J. & Greg A. Lazar. (2017). Next generation antibody drugs: pursuit of the 'high-hanging fruit'. Nature Reviews Drug Discovery. 17(3). 197–223. 564 indexed citations breakdown →

Bernett, Matthew J., Seung Y. Chu, Irene Leung, et al.. (2013). Immune suppression in cynomolgus monkeys by XPro9523. mAbs. 5(3). 384–396. 22 indexed citations

Moore, Gregory L., Erik Pong, Duc-Hanh T. Nguyen, et al.. (2011). A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. mAbs. 3(6). 546–557. 89 indexed citations

Zalevsky, Jonathan, Aaron K. Chamberlain, Holly M. Horton, et al.. (2010). Enhanced antibody half-life improves in vivo activity. Nature Biotechnology. 28(2). 157–159. 449 indexed citations

Moore, Gregory L., Hsing Chen, Sher Karki, & Greg A. Lazar. (2010). Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. mAbs. 2(2). 181–189. 193 indexed citations

10.

Richards, John O., Sher Karki, Greg A. Lazar, et al.. (2008). Optimization of antibody binding to FcγRIIa enhances macrophage phagocytosis of tumor cells. Molecular Cancer Therapeutics. 7(8). 2517–2527. 235 indexed citations

11.

Chu, Seung Y., Igor Voštiar, Sher Karki, et al.. (2008). Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies. Molecular Immunology. 45(15). 3926–3933. 119 indexed citations

12.

Desjarlais, John R., Greg A. Lazar, Eugene A. Zhukovsky, & Seung Y. Chu. (2007). Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective. Drug Discovery Today. 12(21-22). 898–910. 96 indexed citations

13.

Lazar, Greg A., Wei Dang, Sher Karki, et al.. (2006). Engineered antibody Fc variants with enhanced effector function. Proceedings of the National Academy of Sciences. 103(11). 4005–4010. 590 indexed citations breakdown →

14.

Lazar, Greg A., John R. Desjarlais, Jonathan Jacinto, Sher Karki, & Philip W. Hammond. (2006). A molecular immunology approach to antibody humanization and functional optimization. Molecular Immunology. 44(8). 1986–1998. 78 indexed citations

15.

Song, Guang‐Ling, Greg A. Lazar, Tanja Kortemme, et al.. (2005). Rational Design of Intercellular Adhesion Molecule-1 (ICAM-1) Variants for Antagonizing Integrin Lymphocyte Function-associated Antigen-1-dependent Adhesion. Journal of Biological Chemistry. 281(8). 5042–5049. 41 indexed citations

16.

Zhang, Wei, Miriam Hirshberg, Stephen H. McLaughlin, et al.. (2004). Biochemical and Structural Studies of the Interaction of Cdc37 with Hsp90. Journal of Molecular Biology. 340(4). 891–907. 60 indexed citations

17.

Desjarlais, John R. & Greg A. Lazar. (2003). Negative design for improved therapeutic proteins. Trends in biotechnology. 21(10). 425–427. 4 indexed citations

18.

Marshall, Shannon, Greg A. Lazar, Arthur J. Chirino, & John R. Desjarlais. (2003). Rational design and engineering of therapeutic proteins. Drug Discovery Today. 8(5). 212–221. 134 indexed citations

19.

Lazar, Greg A., et al.. (2003). Designing proteins for therapeutic applications. Current Opinion in Structural Biology. 13(4). 513–518. 34 indexed citations

20.

Lazar, Greg A. & Tracy M. Handel. (1998). Hydrophobic core packing and protein design. Current Opinion in Chemical Biology. 2(6). 675–679. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact